NasdaqGS - Delayed Quote • USD
CG Oncology, Inc. (CGON)
At close: 4:00 PM EDT
After hours: 4:07 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 5 |
| Avg. Estimate | -0.37 | -0.41 | -1.59 | -1.89 |
| Low Estimate | -0.53 | -0.57 | -2.11 | -2.41 |
| High Estimate | -0.23 | -0.28 | -1.11 | -1.27 |
| Year Ago EPS | -- | -- | -15.65 | -1.59 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 4 | 4 |
| Avg. Estimate | 180k | 180k | 1.66M | 8.78M |
| Low Estimate | -- | -- | 500k | -- |
| High Estimate | 530k | 530k | 3.53M | 32.5M |
| Year Ago Sales | -- | -- | 204k | 1.66M |
| Sales Growth (year/est) | -- | -- | 713.70% | 428.90% |
Earnings History
| CURRENCY IN USD | 3/31/2024 | |||
|---|---|---|---|---|
| EPS Est. | -- | -- | -- | -0.29 |
| EPS Actual | -- | -- | -- | -0.36 |
| Difference | -- | -- | -- | -0.07 |
| Surprise % | -- | -- | -- | -24.10% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.37 | -0.41 | -1.59 | -1.89 |
| 7 Days Ago | -0.35 | -0.4 | -1.51 | -1.84 |
| 30 Days Ago | -0.32 | -0.35 | -1.44 | -1.7 |
| 60 Days Ago | -0.37 | -0.39 | -1.59 | -1.87 |
| 90 Days Ago | -0.4 | -0.42 | -1.62 | -1.87 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | 1 | 2 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | 1 | 1 | 1 |
Growth Estimates
| CURRENCY IN USD | CGON | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 9.10% |
| Next Qtr. | -- | -- | -- | 11.30% |
| Current Year | 89.80% | -- | -- | 5.80% |
| Next Year | -18.90% | -- | -- | 12.50% |
| Next 5 Years (per annum) | -- | -- | -- | 11.42% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Upgrade | Goldman Sachs: Neutral to Buy | 5/14/2024 |
| Upgrade | Goldman Sachs: Neutral to Buy | 5/13/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/10/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 5/6/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/6/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 5/2/2024 |
Related Tickers
KYTX Kyverna Therapeutics, Inc.
12.43
-6.75%
AVBP ArriVent BioPharma, Inc.
18.88
-5.08%
CRNX Crinetics Pharmaceuticals, Inc.
48.63
-3.78%
DYN Dyne Therapeutics, Inc.
31.25
-0.89%
LRMR Larimar Therapeutics, Inc.
7.47
-5.44%
APGE Apogee Therapeutics, Inc.
46.04
-3.82%
ERAS Erasca, Inc.
2.5900
+6.15%
CGEM Cullinan Therapeutics, Inc.
22.65
-2.12%
ARVN Arvinas, Inc.
35.23
-2.00%
CRGX CARGO Therapeutics, Inc.
20.84
-0.81%